menu
    • menu
    [{"orgOrder":0,"company":"Ophirex","sponsor":"AXA IM Alts","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Varespladib Methyl","moa":"PLA2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Ophirex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ophirex \/ AXA IM Alts","highestDevelopmentStatusID":"8","companyTruncated":"Ophirex \/ AXA IM Alts"}]

    Find Clinical Drug Pipeline Developments & Deals by Ophirex

    Menu

    Ophirex

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ophirex

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed

                            Ophirex

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varespladib Methyl

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : AXA IM Alts

                            Deal Size : $37.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Ophirex Completes $37 Million Series B Financing to Advance Development of Broad-Spectrum Snakebite Treatment

                            Details : Ophirex’s lead drug candidate, LY333013 (varespladib methyl), blocks sPLA2, a nearly ubiquitous and often highly toxic component of venom present in at least 95 percent of snake venoms.

                            Product Name : LY333013

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 01, 2023

                            Lead Product(s) : Varespladib Methyl

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : AXA IM Alts

                            Deal Size : $37.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth